Brainsway Ltd. (BWAY) Form 6-K — Jun 9, 2026
BrainsWay presented new 12-month durability data for its SWIFT accelerated Deep TMS protocol at the Clinical TMS Society Annual Meeting, revealing that over 80% of patients remained in remission one year after treatment. The study, involving 65 patients from a prior pivotal trial, showed a dramatic decline in severe functional impairment from 85% at baseline to 0% at 12 months, with less than 25% of patients requiring medication changes or additional TMS courses.
Key figures
- Consent rate
- 73%
- Remission rate 12mo
- >80%
- Pivotal trial completers
- 89
- Durability trial participants
- 65
- Patients with medication change
- <25%
- Severe functional impairment 12mo
- 0%
- Severe functional impairment baseline
- 85%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.